The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.

Meanwhile, Pfizer reckons it's found the right dose for its KAT6.

Conference activity picks up, with the big one – ASCO – at the end of the month.

The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.

The company heralds a pivotal win with its menin inhibitor, but investors want to see data.

Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.

Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.

Menin, BTK and a Car-T skirmish featured over the ASH weekend.

Enzomenib might be the most promising agent so far, on a cross-trial basis.

The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.